Latest News and Press Releases

- Biologics License Application (BLA) for IV efgartigimod accepted for review by U.S. Food and Drug Administration (FDA) for generalized myasthenia gravis (gMG) - Pre-approval access program opened...

Regulated Information/Inside Information argenx Announces FDA Acceptance of BLA Filing for Efgartigimod for the Treatment of Generalized Myasthenia Gravis If approved, efgartigimod will be the...

February 25, 2021 Breda, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and...

Regulated information February 5, 2021 Breda, the Netherlands / Ghent, Belgium — argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people...

Regulated information — Inside information February 4, 2021 Breda, the Netherlands — argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people...

Regulated information — Inside information February 2, 2021, 10:15 PM ESTFebruary 3, 2021, 4:15 AM CET Breda, the Netherlands — argenx SE (Euronext & Nasdaq: ARGX), a global immunology company...

      -No observed elevation of cholesterol markers related to treatment with efgartigimod February 2, 2021 Breda, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), today provided a...

Regulated information — Inside information February 1, 2021 Breda, the Netherlands — argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people...

Regulated Information/Inside Information Independent data monitoring committee confirmed go-forward decision based on evaluation of interim safety as well as efficacy assessments that surpassed...

Submitted Biologics License Application (BLA) to U.S. Food and Drug Administration (FDA) for efgartigimod in generalized myasthenia gravis (gMG)Initiated 50-patient gMG bridging study of...